Abstract
BackgroundVariation in dose and duration of corticosteroids for childhood-onset steroid-sensitive nephrotic syndrome occurs worldwide, likely reflecting the evolving evidence on optimal dosing and variable severity of the disease observed between patients. We conducted a study to determine the associations between site, physician, and patient factors, and average daily corticosteroid dose and duration of therapy.MethodsData were derived from the Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project, an observational longitudinal study from 2013 to 2019 of children with nephrotic syndrome involving pediatric nephrologists in 11 sites across Canada. The primary outcome was average daily corticosteroid dose prescribed per episode of proteinuria, reported as mg/m2 prednisone equivalents. Secondary outcome was duration of treatment for each episode of proteinuria in days. Exposure variables were categorized into site-, physician-, and patient-level variables.ResultsIn total, 328 children, median age at enrollment of 4.3 years old (interquartile range [IQR], 3.6), participated and were followed for a median time of 2.62 years (IQR, 2.6). The observed variability in average daily corticosteroid dose and in duration of therapy was mostly attributed to the site where the patient was treated. Accounting for between patient, physician, and site differences, average daily corticosteroid dose decreased with increasing age (beta coefficient, −0.07; 95% confidence interval [95% CI], −0.09 to −0.05], P<0.001). African and Indigenous ethnicity was associated with longer treatment duration compared with White patients (beta coefficient: African, 42.29, 95% CI, 7.85 to 76.73, P=0.02; Indigenous, 29.65, 95% CI, 2.79 to 56.52, P=0.03).ConclusionsWe found practice variation with respect to corticosteroid prescriptions across 11 Canadian sites, and that variation is mostly explained at the site level. Age and ethnicity are important factors to be considered, because they are significantly associated with the average corticosteroid dose and duration of therapy.
Funder
Canadian Institutes of Health Research
Kidney Foundation of Canada
Nephcure Kidney International
University of Calgary’s Cumming School of Medicine
Publisher
American Society of Nephrology (ASN)
Reference22 articles.
1. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature
2. Long-term outcome of primary nephrotic syndrome.
3. The nephrotic syndrome;Arneil;Pediatr Clin North Am,1971
4. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group . KDIGO clinical practice guideline for glomerulonephritis. Available at https://www.kisupplements.org/article/S2157-1716(15)31048-0/fulltext. Accessed November 15, 2021
5. Variability among pediatric nephrologists in the initial therapy of nephrotic syndrome
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献